Entering the 4th decade of Botox (onabotulinumtoxinA): A narrative review of its development and impact on patients and medicine
Medicine (Baltimore)
.
2023 Jul 1;102(S1):e32370.
doi: 10.1097/MD.0000000000032370.
Author
Mitchell F Brin
1
2
Affiliations
1
Allergan/AbbVie, Irvine, CA, USA.
2
University of California, Irvine, CA, USA.
PMID:
37499076
PMCID:
PMC10374183
DOI:
10.1097/MD.0000000000032370
No abstract available
Publication types
Review
Research Support, Non-U.S. Gov't
MeSH terms
Botulinum Toxins, Type A* / therapeutic use
Humans
Medicine*
Migraine Disorders*
Treatment Outcome
Substances
Botulinum Toxins, Type A